PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.95%
R&D growth while TRAW reduces spending. John Neff would investigate strategic advantage.
24.63%
G&A growth while TRAW reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
3.65%
Other expenses change of 3.65% while TRAW maintains costs. Bruce Berkowitz would investigate efficiency.
26.14%
Operating expenses growth while TRAW reduces costs. John Neff would investigate differences.
26.14%
Total costs growth while TRAW reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
3.65%
D&A change of 3.65% while TRAW maintains D&A. Bruce Berkowitz would investigate efficiency.
-26.20%
EBITDA decline while TRAW shows 0.80% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Operating income decline while TRAW shows 0.80% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-1.70%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-26.43%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.43%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-26.52%
EPS decline while TRAW shows 14.41% growth. Joel Greenblatt would examine position.
-26.52%
Diluted EPS decline while TRAW shows 14.41% growth. Joel Greenblatt would examine position.
0.09%
Share count reduction exceeding 1.5x TRAW's 39.40%. David Dodd would verify capital allocation.
0.09%
Diluted share reduction exceeding 1.5x TRAW's 39.40%. David Dodd would verify capital allocation.